German biotechnology company BioNTech SE (Nasdaq:BNTX) reported on Monday total revenue of EUR3.2bn for the second quarter of 2022, down from EUR5.3bn in the same period a year ago.
In the first six months of the year, total revenue grew to EUR9.6bn from EUR7.4bn a year earlier.
Net profit for the second quarter amounted to EUR1.7bn, compared with EUR2.8bn in the second quarter last year, with the first-half figures showing an increase to EUR5.4bn from EUR3.9bn in the first six months of 2021.
The company fell short of sales and earnings expectations in the second quarter after the European Commission renegotiated its COVID-19 vaccine contract. Doses scheduled for delivery in June-August 2022 will now be delivered in September through to the fourth quarter of 2022. This change of delivery schedule did not impact the company's full-year 2022 revenue guidance or the full-year commitment of doses to be delivered to EU member states in 2022.
BioNTech also said that, with its partner Pfizer Inc (NYSE:PFE), it plans to launch a clinical trial this month of a COVID-19 vaccine adapted to the BA.4 and BA.5 variants of Omicron.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV